References
1.
Phatak PD, Sham RL, Raubertas RF,
et al. Prevalence of hereditary hemochromatosis in 16031 primary care
patients. Ann Intern Med. 1998;129(11):954-961.
https://doi:10.7326/0003-4819-129-11_Part_2-199812011-00006
2. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and
management of hemochromatosis: 2011 practice guideline by the American
Association for the Study of Liver Diseases. Hepatology.2011;54(1):328-343.
https://doi:10.1002/hep.24330
3. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Blackwell
Science Ltd, Oxford; 2001. https://doi:10.1002/9780470696705
4. Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline:
Hereditary Hemochromatosis. Am J Gastroenterol.2019;114(8):1202-1218.
https://doi:10.14309/ajg.0000000000000315
5. Cullen LM, Gao X, Easteal S, Jazwinska EC. The hemochromatosis 845
G–>A and 187 C–>G mutations: prevalence
in non-Caucasian populations. Am J Hum Genet.1998;62(6):1403-1407.
https://doi:10.1086/301878
6. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of
845G–> A (C282Y) HFE hereditary haemochromatosis
mutation in the USA. Lancet. 2002;359(9302):211-218.
https://doi:10.1016/S0140-6736(02)07447-0
7. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and
iron-overload screening in a racially diverse population. N Engl J
Med. 2005;352(17):1769-1778.
https://doi:10.1056/NEJMoa041534
8. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A
population-based study of the biochemical and clinical expression of the
H63D hemochromatosis mutation. Gastroenterology.2002;122(3):646-651.
https://doi:10.1016/s0016-5085(02)80116-0
9. Wilson MM, Al-Wakeel H, Said F, El-Ghamrawy M, Assaad M, El-Beshlawy
A. Study of the effect of HFE gene mutations on iron overload in
Egyptian thalassemia patients. Egypt J Med Hum Genet.2015;16(2):129-133.
https://doi:10.1016/j.ejmhg.2015.02.002
10. Melis MA, Cau M, Deidda F, Barella S, Cao A, Galanello R. H63D
mutation in the HFE gene increases iron overload in beta-thalassemia
carriers. Haematologica. 2002;87(3):242-245. URL:
https://pubmed.ncbi.nlm.nih.gov/11869934/
11. Yang J, Lun Y, Shuai X, Liu T, Wu Y. Late-onset Hemochromatosis:
Co-inheritance of beta-thalassemia and Hereditary Hemochromatosis in a
Chinese Family: A Case Report and Epidemiological Analysis of Diverse
Populations. Intern Med. 2018;57(23):3433-3438.
https://doi.org/10.2169/internalmedicine.8628-16
12. Cao A, Galanello R. Beta-thalassemia. Genet Med.2010;12(2):61-76.
https://doi:10.1097/GIM.0b013e3181cd68ed
13. Demir A, Yarali N, Fisgin T, Duru F, Kara A. Most reliable indices
in differentiation between thalassemia trait and iron deficiency anemia.Pediatr Int . 2002;44(6):612-616.
https://doi:10.1046/j.1442-200X.2002.01636.x
14. Lands R, Isang E. Secondary Hemochromatosis due to Chronic Oral Iron
Supplementation. Case Rep Hematol. 2017;2017:2494167.
https://doi.org/10.1155/2017/2494167
15. Knox-Macaulay HH, Weatherall DJ, Clegg JB, Pembrey ME. Thalassaemia
in the British. Br Med J. 1973;3(5872):150-155.
https://doi:10.1136/bmj.3.5872.150
16. Bishop RC, Bethell FH. Hereditary hypochromic anemia with
transfusion hemosiderosis treated with pyridoxine: report of a case.N Engl J Med. 1959;261:486-489.
https://doi:10.1056/NEJM195909032611004
17. Milic S, Mikolasevic I, Orlic L, et al. the role of iron and iron
overload in chronic liver disease. Med Sci Monit.2016;22:2144-2151.
https://doi:10.12659/msm.896494
18. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851
patients with hemochromatosis: symptoms and response to treatment.Am J Med. 1999;106(6):619-624.
https://doi:10.1016/s0002-9343(99)00120-5
19. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron
overload. Blood. 2012;120(18):3657-3669.
https://doi:10.1182/blood-2012-05-370098
20. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D,
Strohmeyer G. Long-term survival in patients with hereditary
hemochromatosis. Gastroenterology. 1996;110(4):1107-1119.
https://doi:10.1053/gast.1996.v110.pm8613000